risperidone has been researched along with Inflammation in 21 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, placebo-controlled study involved 75 patients with schizophrenia who randomly received low dose (100 mg/day) or high dose minocycline (200 mg/day) or placebo added to risperidone." | 9.30 | The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. ( Kosten, TR; Wu, R; Zhang, L; Zhang, XY; Zhao, J; Zheng, H, 2019) |
| "This study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia." | 9.27 | No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia. ( Fan, X; Liu, F; Ruan, Y; Xie, L; Xu, X; Zeng, Y; Zhang, B; Zhao, J, 2018) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 7.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| "Risperidone was started with a daily dose of 0." | 6.94 | Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Amirimoghaddam-Yazdi, Z; Moghaddam, HS; Mohammadi, MR; Momtazmanesh, S, 2020) |
| "Patients with schizophrenia were randomized to monotherapy with risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, perphenazine or haloperidol in a 6-week pharmacological trial." | 6.23 | The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia. ( Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L, 2024) |
| "A double-blind, placebo-controlled study involved 75 patients with schizophrenia who randomly received low dose (100 mg/day) or high dose minocycline (200 mg/day) or placebo added to risperidone." | 5.30 | The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. ( Kosten, TR; Wu, R; Zhang, L; Zhang, XY; Zhao, J; Zheng, H, 2019) |
| "This study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia." | 5.27 | No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia. ( Fan, X; Liu, F; Ruan, Y; Xie, L; Xu, X; Zeng, Y; Zhang, B; Zhao, J, 2018) |
| "Steady-state serum concentrations of individual patients under therapy with risperidone (n=45), aripiprazole (n=30), olanzapine (n=24), and quetiapine (n=166) were retrospectively analyzed during a period of inflammation by Spearman's Rho correlation analysis." | 3.96 | Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting. ( Deckert, J; Menke, A; Scherf-Clavel, M; Unterecker, S; Weidner, A, 2020) |
| "The aim of this study was to find out whether elevated serum levels (≥5 mg/l) of C-reactive protein (CRP), an established laboratory marker of infection and inflammation, are associated with increased serum concentrations of the atypical antipsychotic drugs clozapine, quetiapine, and risperidone." | 3.83 | Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. ( Falter, T; Hefner, G; Hiemke, C; Shams, ME; Unterecker, S, 2016) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 3.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| "Risperidone was started with a daily dose of 0." | 2.94 | Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Amirimoghaddam-Yazdi, Z; Moghaddam, HS; Mohammadi, MR; Momtazmanesh, S, 2020) |
| "Inflammation is closely linked with behavioral parameters such as exercise, sleep, alcohol abuse, and smoking, as well as with medical comorbidities including coronary artery disease, obesity and insulin resistance, osteoporosis, and pain." | 2.45 | Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. ( Goldstein, BI; Kemp, DE; McIntyre, RS; Soczynska, JK, 2009) |
| " We report that low-dose risperidone treatment results in global immunosuppression in mice, observed following 5 days of dosing and exacerbated with longer term drug treatment (4 weeks)." | 1.51 | The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. ( Barlow, D; Beauchemin, M; Houseknecht, KL; May, M; Vary, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Zhang, Y | 1 |
| Tao, S | 1 |
| Coid, J | 1 |
| Wei, W | 1 |
| Wang, Q | 1 |
| Yue, W | 1 |
| Yan, H | 1 |
| Tan, L | 1 |
| Chen, Q | 1 |
| Yang, G | 1 |
| Lu, T | 1 |
| Wang, L | 1 |
| Zhang, F | 1 |
| Yang, J | 1 |
| Li, K | 1 |
| Lv, L | 1 |
| Tan, Q | 1 |
| Zhang, H | 1 |
| Ma, X | 2 |
| Yang, F | 1 |
| Li, L | 1 |
| Wang, C | 1 |
| Zhao, L | 1 |
| Deng, W | 1 |
| Guo, W | 1 |
| Zhang, D | 1 |
| Li, T | 1 |
| León-Ortiz, P | 1 |
| Rivera-Chávez, LF | 1 |
| Torres-Ruíz, J | 1 |
| Reyes-Madrigal, F | 1 |
| Carrillo-Vázquez, D | 1 |
| Moncada-Habib, T | 1 |
| Cassiano-Quezada, F | 1 |
| Cadenhead, KS | 1 |
| Gómez-Martín, D | 1 |
| de la Fuente-Sandoval, C | 1 |
| Zhang, L | 1 |
| Zheng, H | 1 |
| Wu, R | 1 |
| Kosten, TR | 1 |
| Zhang, XY | 1 |
| Zhao, J | 2 |
| Momtazmanesh, S | 1 |
| Amirimoghaddam-Yazdi, Z | 1 |
| Moghaddam, HS | 1 |
| Mohammadi, MR | 1 |
| Akhondzadeh, S | 1 |
| Obuchowicz, E | 1 |
| Bielecka-Wajdman, AM | 1 |
| Paul-Samojedny, M | 1 |
| Nowacka, M | 1 |
| Bahramabadi, R | 1 |
| Samadi, M | 1 |
| Vakilian, A | 1 |
| Jafari, E | 1 |
| Fathollahi, MS | 1 |
| Arababadi, MK | 1 |
| Liu, F | 1 |
| Xie, L | 1 |
| Zhang, B | 1 |
| Ruan, Y | 1 |
| Zeng, Y | 1 |
| Xu, X | 1 |
| Fan, X | 1 |
| Watremez, W | 1 |
| Jackson, J | 1 |
| Almari, B | 1 |
| McLean, SL | 1 |
| Grayson, B | 1 |
| Neill, JC | 1 |
| Fischer, N | 1 |
| Allouche, A | 1 |
| Koziel, V | 1 |
| Pillot, T | 1 |
| Harte, MK | 1 |
| Helland, A | 1 |
| Habib, S | 1 |
| Ulvestad, L | 1 |
| Spigset, O | 1 |
| Scherf-Clavel, M | 1 |
| Weidner, A | 1 |
| Deckert, J | 1 |
| Menke, A | 1 |
| Unterecker, S | 2 |
| May, M | 1 |
| Beauchemin, M | 1 |
| Vary, C | 1 |
| Barlow, D | 1 |
| Houseknecht, KL | 1 |
| Bent, S | 1 |
| Hendren, RL | 1 |
| Hefner, G | 2 |
| Shams, ME | 1 |
| Falter, T | 2 |
| Hiemke, C | 2 |
| da Cruz Jung, IE | 1 |
| Machado, AK | 1 |
| da Cruz, IB | 1 |
| Barbisan, F | 1 |
| Azzolin, VF | 1 |
| Duarte, T | 1 |
| Duarte, MM | 1 |
| do Prado-Lima, PA | 1 |
| Bochi, GV | 1 |
| Scola, G | 1 |
| Moresco, RN | 1 |
| Bruns, K | 1 |
| Yamaguchi, I | 1 |
| Hamada, K | 1 |
| Yoshida, M | 1 |
| Isayama, H | 1 |
| Kanazashi, S | 1 |
| Takeuchi, K | 1 |
| Goldstein, BI | 1 |
| Kemp, DE | 1 |
| Soczynska, JK | 1 |
| McIntyre, RS | 1 |
| McNamara, RK | 1 |
| Jandacek, R | 1 |
| Rider, T | 1 |
| Tso, P | 1 |
| MacDowell, KS | 1 |
| García-Bueno, B | 1 |
| Madrigal, JL | 1 |
| Parellada, M | 1 |
| Arango, C | 1 |
| Micó, JA | 1 |
| Leza, JC | 1 |
| Chen, SL | 1 |
| Lee, SY | 1 |
| Chang, YH | 1 |
| Chen, SH | 1 |
| Chu, CH | 1 |
| Tzeng, NS | 1 |
| Lee, IH | 1 |
| Chen, PS | 1 |
| Yeh, TL | 1 |
| Huang, SY | 1 |
| Yang, YK | 1 |
| Lu, RB | 1 |
| Hong, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Video Assisted Speech Technology to Enhance Functional Language Abilities in Individuals With Autism Spectrum Disorder[NCT04764539] | 6 participants (Actual) | Interventional | 2019-12-01 | Completed | |||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| A Double-blind, Placebo-Controlled, Randomized Study of the Efficacy of Dextromethorphan as Add-On Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia[NCT01189006] | Phase 2/Phase 3 | 161 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in % of correct phonemes in each attempted stimulus (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | percentage of correct phonemes (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 19.75 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 16.24 |
"Participants (aged 4 to 8 years) were given a pre- and post-test 15-minute language sample. MLU was calculated for tests and gain from pre-test to post-test was compared.~NOTE: This measure is calculated based on a change in the number of morphemes per utterance during pre-test and post-test language samples. During a five-minute period, two licensed speech-language pathologists (SLP) observed a parent interacting and talking with their child. Parents Both SLPs transcribed the subjects' speech and calculated a mean length of utterance (MLU) for each subject. MLU was calculated by determining how many bound and free morphemes were included within every spoken utterance produced by a subject. The total number of morphemes produced within the 5-minute period were then divided by total number of utterances, which then produced the MLU for each subject. This procedure was use for determining MLU in both the pre- and post-testing procedures." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Morphemes per utterance (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 0.5387 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 0.2987 |
"15-minute pre- and post-testing was performed using speech recognition software and transcribed by a licensed speech pathologist. Differences pre and post intervention were compared across group and within groups.~NOTE: During our assessment, we used Google's native closed captioning function (a tool which uses machine learning to recognize and transcribe speech) and a third party app, Tactiq Pins, which allows users to keep a transcript of all speaker utterances during a call. We compared our video to the Tactiq Pin transcripts in order to measure any change in the amount of accurately transcribed spoken words between pre-test and post-test language samples. Specific transcription results for each group can be found in the data tables provided." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | % of correctly transcribed words (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 1.388 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 0 |
A type-token ratio measures the total number of unique words in a given segment of language. (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | number of unique words in a segment (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 30.158 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 22.26 |
The change in response rate measures any significant differences in how often children responded to pre- and post-testing stimuli after having received treatment between the iPad Pro and VR goggles groups. A response is considered a verbal or non-verbal reaction (e.g., eye contact, gestures, vocalizations) to the stimuli presented during the therapy sessions. Higher response rates indicate better engagement and responsiveness to the treatment. The change in response rate is calculated as the value at the post-test time point minus the value at the pre-test time point, with positive numbers representing increases and negative numbers representing decreases in response rate. (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Number of responses (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 5.67 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 3.33 |
"Parent observations -- perceptions of changes in their children's motor-speech, behavioral, and social communication skills after having participated in the study~Scale title: Net Positive Changes Score Maximum possible value: 18 Minimum possible value: -2 Higher score is better." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Score on a scale (Mean) |
|---|---|
| Parents of Participants, Who Received VAST Stimuli Via a 2D Format on an iPad Pro | 11 |
| Parents of Participants, Who Received VAST Stimuli Through VR Goggles and Bone Conduction Headphones | 9.67 |
2 reviews available for risperidone and Inflammation
| Article | Year |
|---|---|
Complementary and alternative treatments for autism part 1: evidence-supported treatments.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Complementary Therap | 2015 |
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric | 2009 |
5 trials available for risperidone and Inflammation
| Article | Year |
|---|---|
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perph | 2024 |
The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Cognitive Dysfunction; Double-Bli | 2019 |
Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Anti-Inflammatory Agents; Antioxidants; Antipsychotic Agents; Autism Spectrum Disorder; Child; Child | 2020 |
No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia.
Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Double-Blind Method; Female; Humans; Inflamma | 2018 |
Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.
Topics: Adult; Dextromethorphan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammatio | 2012 |
14 other studies available for risperidone and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Systemic inflammation and cortical neurochemistry in never-medicated first episode-psychosis individuals.
Topics: Antipsychotic Agents; Glutamic Acid; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; N | 2023 |
Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: An in vitro study.
Topics: Animals; Antipsychotic Agents; Cell Differentiation; Cell Survival; Cells, Cultured; Chlorpromazine; | 2017 |
Evaluation of the effects of anti-psychotic drugs on the expression of CD68 on the peripheral blood monocytes of Alzheimer patients with psychotic symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antigens, CD; Antigens, Differentiation, Myelomonocytic; | 2017 |
Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat.
Topics: Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepezil; Female; gamma-A | 2018 |
Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone.
Topics: Antipsychotic Agents; Drug Monitoring; Humans; Inflammation; Male; Middle Aged; Risperidone; Schizop | 2018 |
Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; C-Reactive Protein; | 2020 |
The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.
Topics: Animals; Antipsychotic Agents; Humans; Immunosuppressive Agents; Inflammation; Male; Mice; Mice, Inb | 2019 |
Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Biomarkers; C-Reactive Protein; Clozapine; Female; Hu | 2016 |
Haloperidol and Risperidone at high concentrations activate an in vitro inflammatory response of RAW 264.7 macrophage cells by induction of apoptosis and modification of cytokine levels.
Topics: Animals; Antipsychotic Agents; Apoptosis; Cell Survival; Cytokines; Dose-Response Relationship, Drug | 2016 |
Elevated risperidone serum concentrations during acute inflammation, two cases.
Topics: Acute Disease; Adult; Antipsychotic Agents; C-Reactive Protein; Female; Humans; Inflammation; Middle | 2015 |
Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Anti-Inflammatory Agents; Choline Deficiency; Ethionine; Female; I | 2009 |
Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats.
Topics: Animals; Antipsychotic Agents; C-Reactive Protein; Chronic Disease; Cytokines; Diet, Fat-Restricted; | 2011 |
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Encepha | 2013 |